Danaher Corporation

Danaher reported Q3 sales of $6.6 billion. Core revenue growth excluding respiratory was 5.5%, and total core revenue growth was 3% after an approximately 250 basis point respiratory headwind. Gross profit margin was 58.5%, adjusted operating profit margin was 29% (up 110 basis points), and adjusted diluted EPS was $2.11, up approximately 11.5%. Free cash flow was $1.6 billion in the quarter and $4 billion in the first nine months, with year-to-date free cash flow to net income conversion of 128%. By segment, Biotechnology core revenue rose 5%, Life Sciences rose 4.5%, and Diagnostics core revenue excluding respiratory rose 7%. For Q4, management expects core revenue growth excluding respiratory of 4%-5%, respiratory to be about a 150 basis point headwind, and adjusted operating margin of about 29.5%. For full-year 2026, adjusted diluted EPS guidance was increased to $8.57-$8.62, versus the prior $8.45-$8.60 range, implying double-digit year-over-year EPS growth. Management said 4%-5% core growth excluding respiratory is the starting point for 2027, with formal guidance to come in January.

Julie Sawyer Montgomery framed Danaher’s next chapter as one focused on becoming the defining leader in Life Sciences and Diagnostics through more consistent share gain, better commercial execution, stronger innovation, talent development, and disciplined capital allocation. Her tone was confident but intentionally measured: she repeatedly said the foundation is strong, but execution needs to improve and credibility will be earned through results. She stressed that Danaher should be more connected across operating companies so customers can access the full portfolio, and she tied that to examples in Diagnostics, bioprocessing, and AI-enabled workflows.

Matt Gugino said Q3 outperformed expectations on both growth and earnings, with sales of $6.6 billion, 58.5% gross margin, 29% adjusted operating margin, and $2.11 adjusted EPS. He noted the quarter also generated $1.6 billion of free cash flow, bringing year-to-date free cash flow to $4 billion and conversion to 128% of net income. On outlook, he guided Q4 core growth excluding respiratory to 4%-5%, a 150 basis point respiratory headwind, and about 29.5% adjusted operating margin, while raising full-year 2026 adjusted EPS guidance to $8.57-$8.62.

Analysts pressed management on whether 2027 should accelerate beyond the 4%-5% core growth starting point, especially given improving bioprocessing orders, easing China headwinds, and a recovering academic market. Management said 4%-5% is a reasonable starting point based on current conditions, but the company wants to complete its Q4 planning process before giving a more detailed January outlook. On respiratory, Julie said Danaher is planning around $1.5 billion this year and that is also the right starting point for next year, while cautioning that flu seasons can create a few hundred million dollars of variability.